ANNX vs AVBP: fair value comparison
Annexon, Inc. and ArriVent BioPharma, Inc. Common Stock · Updated 2026-10-19
ANNX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. AVBP has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ANNX currently ranks higher by quality score.
| ANNX | AVBP | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $3.41 | $16.66 |
| 12-month range | $2.68–$6.96 | $15.09–$34.74 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #219 of 301 Healthcare | #220 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: ANNX fair value analysis · AVBP fair value analysis